Sun Pharmaceutical Industries Limited — China drug registrations and re-registration deadlines
7 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2026-11-12.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20181097 | Rivastigmine Hydrogen Tartrate Capsules 重酒石酸卡巴拉汀胶囊 | 2027-05-12 | 2026-11-12 |
| 国药准字HJ20181098 | Rivastigmine Hydrogen Tartrate Capsules 重酒石酸卡巴拉汀胶囊 | 2027-05-12 | 2026-11-12 |
| 国药准字HJ20230051 | Tetrabenazine Tablets 丁苯那嗪片 | 2028-05-11 | 2027-11-11 |
| 国药准字SJ20230006 | ILUMETRI 替瑞奇珠单抗注射液 | 2028-05-25 | 2027-11-25 |
| 国药准字HJ20230113 | Etoricoxib Tablets 依托考昔片 | 2028-10-17 | 2028-04-17 |
| 国药准字HJ20230114 | Etoricoxib Tablets 依托考昔片 | 2028-10-17 | 2028-04-17 |
| 国药准字HJ20230115 | Etoricoxib Tablets 依托考昔片 | 2028-10-17 | 2028-04-17 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.